Journals / Turkish Journal of Gastroenterology / 2012 / Cilt: 23 - Sayı: 6

Terlipresin tedavisi sonrasında geliflen iskemik cilt nekrozu: İki olgu sunumu ve literatürün gözden geçirilmesi

Ischemic skin necrosis following terlipressin therapy: Report of two cases and review of the literature

Pages
788–791
DOI
—
🏛️Bibliographic metadata and full text access for this article are provided via DergiPark.
DergiPark Record ↗
✨

AI Summary & Key Takeaways

AI Insight
⚡ TL;DR(Too Long; Didn't Read)

Even if seen rarely, possible emergence of ischemic complications must be considered.

📌 3 Key Takeaways

🎯
Objective & Hypothesis:Terlipressin is a synthetic vasopressin analogue that is used in the treatment of bleeding esophageal varices and hepatorenal syndrome in patients with cirrhosis.
📊
Key Findings & Data:Hepatorenal syndrome is a form of renal failure seen in patients with cirrhosis, with fatal outcomes.
💡
Conclusion & Impact:Even if seen rarely, possible emergence of ischemic complications must be considered.
🔬Design:Research Article
📍Scope:Comprehensive Sample
⚙️Variables:Domain Parameters

Abstract

Terlipressin is a synthetic vasopressin analogue that is used in the treatment of bleeding esophageal varices and hepatorenal syndrome in patients with cirrhosis. Hepatorenal syndrome is a form of renal failure seen in patients with cirrhosis, with fatal outcomes. Ischemic adverse effects related to terlipressin are rarely observed. Herein, two cases who developed ischemic skin necrosis due to terlipressin usage are presented. Terlipressin therapy was started in two cirrhotic patients with presumptive hepatorenal syndrome. During the therapy, ecchymotic and necrotic changes were observed on the scrotal regions of both patients. Skin lesions were relieved after terlipressin therapy. Biopsy results were consistent with ischemia. Even if seen rarely, possible emergence of ischemic complications must be considered.

Özet

Terlipresin bir sentetik vazopressin analoğu olup, sirotik hastalarda özofagus varis kanamalarında ve hepatorenal sendrom tedavisinde kullanılmaktadır. Hepatorenal sendrom sirozlu hastalarda görülen ve mortal seyredebilen bir böbrek yetmezliği tablosudur. Terlipresine bağlı iskemik yan etkiler oldukça nadir olarak görülmektedir. Burada terlipresin kullanımına bağlı iskemik cilt nekrozu geliflen iki olgu sunulmaktadır. İki sirotik hastada da hepatorenal sendrom düflünülerek terlipresin tedavisine bafllandı. Tedavi devam ederken her iki hastada da skrotal bölgede ekimotik ve nekrotik değifliklikler olduğu gözlendi. Terlipresin tedavisi kesildikten sonra cilt lezyonları düzeldi. Biyopsi sonucu da iskemi ile uyumlu geldi. Her ne kadar oldukça nadir olarak görülse de terlipresin tedavisi sırasında iskemik komplikasyonların ortaya çıkabileceği daima göz önünde bulundurulmalıdır.

🔖

Cite This Article

TAŞLIYURT, T., KUTLUTÜRK, F., ERDEMİR, F., YELKEN, B. M., YILMAZ, A., KISACIK, B., AYTAN, P., KÖSEOĞLU, R. D. (2012). Terlipresin tedavisi sonrasında geliflen iskemik cilt nekrozu: İki olgu sunumu ve literatürün gözden geçirilmesi. Turkish Journal of Gastroenterology, Cilt: 23 - Sayı: 6, 788–791. https://ajindex.com/articles/410296

📄 Full Text PDF Viewer

📄

PDF görüntüleyici hazırlanıyor...

References (16)

  1. Arroyo V, Guevara M, Gines P. Hepatorenal syndrome in cirrhosis: pathogenesis and treatment. Gastroenterology 2002; 122: 1658-76
  2. Gines P, Rodes J. Clinical disorders of renal function in cirrhosis with ascites. In: Arroyo V, Gines P, Rodes J, Schrier RW, Malden MA, eds. Ascites and renal dysfunction in liver disease: pathogenesis, diagnosis, and treatment. New York: Blackwell Science, 1999; 36-62
  3. Gluud LL, Kjaer MS, Christensen E. Terlipressin for hepatorenal syndrome. Cochrane Database Syst Rev 2006 Oct 18; CD005162
  4. Donnellan F, Cullen G, Hegarty JE, McCormick PA. Ischaemic complications of Glypressin in liver disease: a case series. Br J Clin Pharmacol 2007; 64: 550-2
  5. Guevara M, Gines P, Fernandez-Esparrach G. Reversibility of hepatorenal syndrome by prolonged administration of ornipressin and plasma volume expansion. Hepatology 1998; 27: 35-41
  6. Uriz J, Gines P, Cárdenas A, et al. Terlipressin plus albumin infusion: an effective and safe therapy of hepatorenal syndrome. J Hepatol 2000; 33: 43-8
  7. Dagher L, Patch D, Marley R, et al. Review article: pharmacological treatment of the hepatorenal syndrome in cirrhotic patients. Aliment Pharmacol Ther 2000; 14: 515-21
  8. Gines P, Torre A, Terra C, Guevara M. Review article: pharmacological treatment of hepatorenal syndrome. Aliment Pharmacol Ther 2004; 20: 57-64
  9. Hadengue A, GadanoA, Moreau R. Beneficial effects of the two-day administration of terlipressin in patients with cirrhosis and hepatorenal syndrome. J Hepatol 1998; 29: 565- 70
  10. Lee JS, Lee HS, Jung SW, et al. A case of peripheral ischemic complication after terlipressin therapy. Korean J Gastroenterol 2006; 47: 454-7
  11. Lee MY, Chu CS, Lee KT, et al. Terlipressin-related acute myocardial infarction. Kaohsiung J Med Sci 2004; 20: 604- 8
  12. Willems MG, Schoenemann J, Rey C, et al. Ischaemia of the cecum caused by glycylpressin. Leber Magen Darm 1985; 15: 165-8
  13. Schatt W, Wagner-Thiessen E, Lux G. Ischaemic colitis in a patient treated with Glypressin for bleeding oesophageal varices. Hepatogastroenterology 1987; 34: 134-6
  14. Oh JE, Ha JS, Cho DH, et al. A case of ischemic skin necrosis after glypressin therapy in liver cirrhosis. Korean J Gastroenterol 2008; 51: 381-4
  15. Vaccaro F, Giorgi A, Riggio O, et al. Is spontaneous bacterial peritonitis an inducer of vasopressin analogue side-effects? A case report. Dig Liver Dis 2003; 35: 503-6
  16. Mégarbané H, Barete S, Khosrotehrani K, et al. Two observations rais